--- title: "赛诺菲：药物 SAR446597 已获得 FDA 快速通道资格认定" description: "7 月 16 日，赛诺菲发表声明称，美国食品药品监督管理局已授予 SAR446597 快速通道资格认定，该药物是一种一次性玻璃体内基因疗法，用于治疗年龄相关性黄斑变性引起的地图样萎缩。快速通道资格认定流程旨在促进治疗严重疾病和填补未满足医疗需求的药物开发并加快其审评。FDA 设立这一程序旨在帮助患者更早获得重要新药，其适用范围涵盖多种严重疾病。" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/248820917.md" published_at: "2025-07-16T14:14:02.000Z" --- # 赛诺菲：药物 SAR446597 已获得 FDA 快速通道资格认定 > 7 月 16 日，赛诺菲发表声明称，美国食品药品监督管理局已授予 SAR446597 快速通道资格认定，该药物是一种一次性玻璃体内基因疗法，用于治疗年龄相关性黄斑变性引起的地图样萎缩。快速通道资格认定流程旨在促进治疗严重疾病和填补未满足医疗需求的药物开发并加快其审评。FDA 设立这一程序旨在帮助患者更早获得重要新药，其适用范围涵盖多种严重疾病。 7 月 16 日，赛诺菲发表声明称，美国食品药品监督管理局已授予 SAR446597 快速通道资格认定，该药物是一种一次性玻璃体内基因疗法，用于治疗年龄相关性黄斑变性引起的地图样萎缩。快速通道资格认定流程旨在促进治疗严重疾病和填补未满足医疗需求的药物开发并加快其审评。FDA 设立这一程序旨在帮助患者更早获得重要新药，其适用范围涵盖多种严重疾病。 ### Related Stocks - [SNYNF.US - 赛诺菲](https://longbridge.com/zh-CN/quote/SNYNF.US.md) - [SNY.US - 赛诺菲集团](https://longbridge.com/zh-CN/quote/SNY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Looking Into Altria Group Inc's Recent Short Interest | Altria Group Inc's short interest has decreased by 7.37%, with 44.24 million shares sold short, representing 2.64% of av | [Link](https://longbridge.com/zh-CN/news/276075820.md) | | Artisan Partners Ltd Partnership Discloses 10.11% Stake In Pearson As Of 11 Feb, Says Filing | Pearson PLC :PEARSON PLC - HOLDING(S) IN COMPANYARTISAN PARTNERS LIMITED PARTNERSHIP DISCLOSES 10.11% STAKE IN PEARSON A | [Link](https://longbridge.com/zh-CN/news/276068264.md) | | Sanofi: Beyfortus Study Shows Benefit For Infants Beyond First RSV Season | Sanofi announced that a study on its RSV immunization program using Beyfortus showed a significant reduction in RSV-rela | [Link](https://longbridge.com/zh-CN/news/276038221.md) | | What To Expect From Analog Devices’s (ADI) Q4 Earnings | Analog Devices (ADI) will report Q4 earnings this Wednesday. Last quarter, it exceeded revenue expectations by 2.1%, wit | [Link](https://longbridge.com/zh-CN/news/276090818.md) | | REG - RELX PLC - Director/PDMR Shareholding | RELX PLC announced changes in director shareholdings. CEO Erik Engstrom increased his holdings to 1,327,129 shares, whil | [Link](https://longbridge.com/zh-CN/news/276101908.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。